1
|
Liu X, Li Q, Wang Y, Crawford M, Bhupal PK, Gao X, Xie H, Liang D, Cheng YSL, Liu X, Tsai RY. Designing a Mucoadhesive ChemoPatch to Ablate Oral Dysplasia for Cancer Prevention. SMALL (WEINHEIM AN DER BERGSTRASSE, GERMANY) 2022; 18:e2201561. [PMID: 35587597 PMCID: PMC9233056 DOI: 10.1002/smll.202201561] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/11/2022] [Revised: 04/20/2022] [Indexed: 06/03/2023]
Abstract
Oral cancer has a high mortality rate, and its treatment often causes debilitating complications. More than 90% of oral cancers are oral squamous cell carcinomas (OSCCs) that may develop from clinically recognizable oral premalignant lesions (OPLs). To eradicate OPLs before they turn into cancers, a non-invasive topical formulation is developed based on a novel combination of synergistically acting oxaliplatin (OXP) and mycophenolate (MPS) embedded in a controlled-release mucoadhesive patch fabricated by computer-aided 3D printing. After multiple rounds of testing and optimization, a v6.4 ChemoPatch is designed, which shows sustained release of OXP and MPS in vitro, minimal side leakage of drugs, an average elastic modulus of 2.38 MPa, and suitable drug stability at 4 °C or below for up to 12 months. In vivo analyses show almost all patches adhere to the dorsal tongue surface for 4 hours, and display a sustained release of OXP and MPS to tongue tissue for 3-4 hours. When applied in the 4-nitroquinoline-1-oxide-induced OPL rat model, the OXP-MPS patch significantly ablates dysplastic lesions with no damage to normal epithelial cells and minimal systemic absorption and side effects. This study reports the design of a novel mucoadhesive ChemoPatch as a noninvasive therapy to treat OPLs.
Collapse
Affiliation(s)
- Xiaoqin Liu
- Institute of Biosciences and Technology, Texas A&M Health Science Center; Houston, TX 77030, USA
| | - Qian Li
- Department of Biomedical Sciences, Texas A&M University College of Dentistry; Dallas, TX 75246, USA
| | - Yang Wang
- College of Pharmaceutical Sciences, Texas Southern University; Houston, TX 77004, USA
| | - Madeleine Crawford
- Institute of Biosciences and Technology, Texas A&M Health Science Center; Houston, TX 77030, USA
| | - Parnit K. Bhupal
- Institute of Biosciences and Technology, Texas A&M Health Science Center; Houston, TX 77030, USA
| | - Xiuqing Gao
- College of Pharmaceutical Sciences, Texas Southern University; Houston, TX 77004, USA
| | - Huan Xie
- College of Pharmaceutical Sciences, Texas Southern University; Houston, TX 77004, USA
| | - Dong Liang
- College of Pharmaceutical Sciences, Texas Southern University; Houston, TX 77004, USA
| | - Yi-Shing Lisa Cheng
- Department of Diagnostic Sciences, Texas A&M University College of Dentistry; Dallas, TX 75246, USA
| | - Xiaohua Liu
- Department of Biomedical Sciences, Texas A&M University College of Dentistry; Dallas, TX 75246, USA
| | - Robert Y.L. Tsai
- Institute of Biosciences and Technology, Texas A&M Health Science Center; Houston, TX 77030, USA
- Department of Translational Medical Sciences, Texas A&M Health Science Center; Houston, TX 77030, USA
| |
Collapse
|